Our study demonstrated the clinical feasibility of exploring a synthetic lethal regimen of the combined inhibition of PLK1 and ROCK to defeat KRAS-mutant cancer through a mechanism that involves activation of tumor suppressor P21. This evidence concerns the gene PLK1 and cancer.